Rationale: There are no studies on withdrawal of inhaled corticosteroids in patients on long-
term triple therapy in the absence of frequent exacerbations. Objectives: To evaluate the …

Background Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …

Background We compared the efficacy and safety of indacaterol and tiotropium in patients
with severe chronic obstructive pulmonary disease (COPD) and a history of at least one …

Background Previous studies have highlighted a relationship between reduction in rate of
exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood …

Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …

Background We evaluated the effect of dual, longacting inhaled bronchodilator treatment on
exacerbations in patients with severe and very severe chronic obstructive pulmonary …

Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …

Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …

Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …

Rationale: Indacaterol is the first once-daily, long-acting inhaled β2-agonist bronchodilator
studied in patients with chronic obstructive pulmonary disease (COPD). Objectives: To …